{"id":"W3167585411","doi":"10.1093/ecco-jcc/jjab073.108","title":"DOP69 Ozanimod for induction treatment of Moderate-to-Severe Ulcerative Colitis: Results from a systematic literature review and network meta-analyses","year":2021,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Tofacitinib; Ulcerative colitis; Vedolizumab; Adalimumab; Infliximab; Internal medicine; Golimumab; Population; Placebo; Ixekizumab; Ustekinumab; Clinical trial; Secukinumab; Dermatology; Disease; Psoriatic arthritis; Pathology; Rheumatoid arthritis; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02165904,0.002409329,0.01541522,0.005749091,0.0004434509,0.002538814,0.002290514,0.001899396,0.003737229],"category_scores_gemma":[0.04147493,0.001317707,0.03678673,0.006569491,0.0007784238,0.001714716,0.001590743,0.001713598,0.0003348096],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002151402,"about_ca_system_score_gemma":0.002122777,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005281597,"about_ca_topic_score_gemma":0.01138936,"domain_scores_codex":[0.9777558,0.01457522,0.003975938,0.001792776,0.001541819,0.0003584364],"domain_scores_gemma":[0.9659711,0.02576981,0.005388013,0.0008953136,0.001569294,0.0004064937],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.003975029,0.00002508018,0.00411434,0.1329271,0.8513761,0.00008715308,0.0000579244,0.0006201797,0.0001351472,0.0001028303,0.0003481092,0.006231045],"study_design_scores_gemma":[0.001840911,0.000241984,0.003687034,0.006202125,0.9866663,0.00006249337,0.00003300999,0.0003000314,0.00006067564,0.0001913801,0.0006950283,0.00001910787],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02175065,0.9733794,0.001473879,0.0003807766,0.0002202986,0.0006965732,0.001363389,0.00005389858,0.0006811934],"genre_scores_gemma":[0.6066051,0.3836018,0.004133701,0.001364109,0.0003453009,0.00179825,0.001683693,0.00006078732,0.0004072897],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02165904,"threshold_uncertainty_score":0.1145453,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04021175715449751,"score_gpt":0.3107539729038701,"score_spread":0.2705422157493726,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}